Alpha Teknova, Inc. key statistics and ratios
In fiscal 2025, Alpha Teknova, Inc. had return on equity of -22.8% and a net margin of -42.6%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Net margin | 11.4% | −26.6% | −114.6% | −100.3% | −70.9% | −42.6% | −38.4% |
| Return on equity | 21.3% | −12.3% | −39.1% | −38.7% | −31.0% | −22.8% | −25.5% |
| Return on assets | 5.7% | −8.5% | −29.8% | −26.2% | −21.6% | −15.5% | −16.8% |
| Effective tax rate | 24.5% | — | — | — | — | — | — |
| R&D as % of revenue | 4.8% | 11.7% | 18.7% | 15.2% | 7.3% | 5.4% | 5.1% |
Financial health
- Short-term assets cover short-term liabilities $31m of assets due within a year against $7m of liabilities due within a year.
- Short-term assets cover long-term liabilities $31m short-term assets against $26m of longer-dated liabilities.
- More cash than debt $6m of cash against $13m of debt.
- Debt below 40% of shareholders' equity Debt is 21% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 8% to 21% over five years.
- A year's operating cash flow covers at least 20% of debt −$6m of operating cash flow against $13m of debt.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Moat
Weak moat
How hard Alpha Teknova's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Cash operating profit has been a median -13.8% of total assets over 5 years.
- Pricing power 5 / 20
Gross margin has been a median 35.6%, moving by 10.9 percentage points (standard deviation) across 6 years.
- Durability 10 / 20
Operating margin has been a median -52.4%; its worst year was -135.4%.
- Cash conversion 0 / 20
Free cash flow was positive in 0 of 6 years, at a median -39.7% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (18 before it).
Compare with peers
- Omniab, Inc. statistics
- Rapid Micro Biosystems, Inc. statistics
- Champions Oncology, Inc. statistics
- Precipio, Inc. statistics
- 908 Devices Inc. statistics
Head to head: OABI vs TKNORPID vs TKNOCSBR vs TKNO
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies